IP Library Granted Patent US 7,858,306
Granted Patent B2
US 7,858,306 · App. 11/482,514 · Granted Dec 28, 2010

HSD3B1 sequence variants

Assignee: Mayo Foundation for Medical Education and Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,306
App. No.
11/482,514
Granted
Dec 28, 2010
Kind
B2
Abstract

Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.

Claims (9)

1. A vector comprising an isolated nucleic acid molecule consisting essentially of:

a) a sequence of ten to 100 contiguous nucleotides as set forth in SEQ ID NO:5, wherein the nucleotides are in the order shown in SEQ ID NO:5, and wherein said sequence includes nucleotide 166, 287, 724, 933, 939, or 1017 of SEQ ID NO:5, with the proviso that the nucleotide at position 166 is thymine, the nucleotide at position 287 is thymine, the nucleotide at osition 724 is adenine, the nucleotide at position 933 is cytosine, the nucleotide at position 939 is adenine, or the nucleotide at position 1017 is adenine;

b) a sequence of ten to 100 contiguous nucleotides as set forth in SEQ ID NO:1, wherein the nucleotides are in the order shown in SEQ ID NO:1, and wherein said sequence includes nucleotide 735, 1083, or 5254 of SEQ ID NO:1, with the proviso that the nucleotide at position 735 is thymine, the nucleotide at position 1083 is adenine, or the nucleotide at position 5254 is cytosine; or

c) a sequence fully complementary to a) or b).

2. The vector of claim 1 , wherein said nucleic acid molecule is from 20 to 50 nucleotides in length.

3. An isolated nucleic acid encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6, with the proviso that the amino acid sequence of said polypeptide comprises an amino acid sequence variant at residue 96 or residue 242 relative to the amino acid sequence of SEQ ID NO:6.

4. The isolated nucleic acid of claim 3 , wherein said amino acid sequence variant is a phenylalanine at residue 96 or an asparagine at residue 242.

5. An isolated HSD3B1 polypeptide, wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:6, with the proviso that said polypeptide comprises an amino acid sequence variant at residue 96 or residue 246 relative to the amino acid sequence set forth in SEQ ID NO:6.

6. The isolated polypeptide of claim 5 , wherein said amino acid sequence variant is a phenylalanine at residue 96 or an asparagine at residue 242.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 8, 2008
From: MAYO FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021497/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2006
From: WEINSHILBOUM, RICHARD M.; PELLEYMOUNTER, LINDA L.; WIEBEN, ERIC D.; SALAVAGGIONE, ORESTE; WANG, LIEWEI
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 018198/0527 →
Continuity (2)
Provisional Application 6069721200 · Jul 7, 2005
Related Publication 20090023136A1 · Jan 22, 2009